Defence Therapeutics
Main (gene editing) focus: Novel methods for delivery of gene-editing systems
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:DTCFF)
Location: Vancouver, British Columbia, Canada
Website: https://defencetherapeutics.com/
Defence Therapeutics develops a proprietary platform called ACCUMTM, which enables precision delivery of vaccine antigens or drugs to target cells. The company recently announced strong in vitro results for the delivery of the CRISPR-Cas9 system using ACCUMTM technology. The company now seeks collaborations in the gene-editing space.